Curium to acquire Lantheus in $8 billion deal, offering $102.5 per share with upside potential

Curium announced it will purchase radiopharmaceutical company Lantheus in a transaction valued at about $8 billion.

The agreement sets the purchase price at $102.5 for each Lantheus share, and includes an earnout provision that could add roughly $12 per share if certain performance targets are met.

The acquisition expands Curium’s portfolio in the nuclear imaging market, giving it broader access to diagnostic agents and related technologies.

In a separate development, Sandoz resolved a price-fixing investigation, though details of the settlement were not disclosed in the brief.